Kythera Biopharmaceuticals

KYTHERA Biopharmaceuticals, Inc. was a privately held biopharmaceutical company focused on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company's lead product, KYBELLA (deoxycholic acid injection), was the first and only FDA-approved non-surgical treatment for contouring moderate to severe submental fullness — commonly referred to as a double chin. When injected into subcutaneous fat, KYBELLA causes the destruction of fat cells, which cannot subsequently store or accumulate fat. In addition to KYBELLA, KYTHERA licensed worldwide rights to setipiprant (KYTH-105), an early-stage compound being investigated as a potential treatment for androgenetic alopecia (hair loss). The company raised approximately $130 million in funding and was acquired by Allergan in 2015 for approximately $2.1 billion, reflecting the commercial value of its non-invasive aesthetic platform.